Acute heart drugs should be reconsidered for Maori and Pacific Islanders

Researchers at the University of Otago, New Zealand, say standard medication used for acute heart disease should be reconsidered for some Maori and Pacific Island patients because of drug resistance caused by high rates of Group A streptococcal infection, the same infection which leads to rheumatic fever.

The new study recently published in the prestigious British Journal Clinical Pathology confirms research from that with are more likely to have resistance to the standard heart drug streptokinase (SK).

“Many people living in communities with high endemic levels of Group A strep, have been previously infected by Group A streptococcus bacteria and will have antibodies to streptokinase. There’s therefore a real risk that when they have a heart attack and are given this drug it will not work for them,” explains Dr. Garry Nixon from the Department of General Practice and Rural Health in Dunedin.

The study involved 180 patients from the Hokianga, Thames and Central Otago admitted to hospital with a suspected heart attack.

“It’s clear from our results that patients in the Hokianga, the rural community with the highest proportion of Maori and lowest socio-economic status, have resistance to streptokinase medication which is 2.8 times higher than in Central Otago, with the lowest proportion of Maori and higher socio-economic status.”

Dr. Nixon says these very significant differences mean that newer fibrinolytic heart drugs should be used for patients with heart attacks in predominantly Maori rural communities. However, he says these fibrinolytic agents which are not affected by the immune system, are more expensive than SK drugs, affecting their uptake.

This new research provides strong support for the recent moves away from SK as a standard treatment for heart attacks in rural New Zealand, particularly in predominantly Maori communities.

“Perhaps most importantly this is a timely reminder of the need to exercise caution when translating the results of drug trials carried out on Caucasians to other ethnic groups such and Maori and Pacific Islanders. This is particularly important when a mechanism of , such as the one outlined in this study, has been identified.”

Dr. Nixon also points out that similar major health issues remain in the Pacific Islands where there are very high rates of Group A , increasing rates of ischaemic and a continued reliance on streptokinase as a result of limited health budgets.

People living in Samoa, the Cook Islands, French Polynesia and Tonga have some of the highest rates of rheumatic fever in the world. The study also says that Pacific Islanders living in NZ have an incidence of which is even higher than Maori (1.5-2 times).

Provided by University of Otago

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Recommended for you

FDA to start regulating lab-developed tests

Jul 31, 2014

(AP)—The Food and Drug Administration announced Thursday it will begin regulating laboratory-developed tests, a growing class of medical diagnostics that have never before been subject to federal oversight.

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

User comments

Adjust slider to filter visible comments by rank

Display comments: newest first

ironjustice
not rated yet May 24, 2011
What significance would there be here that the Pacific Islanders ALSO coincidentally have the "highest blood iron levels of anyone" .. ?
"Asians and Pacific Islanders have the highest mean levels
of iron in their blood of all ethnic groups involved, including African Americans, Caucasians, Hispanics, and Native Americans. Hemochromatosis, one of the most common inherited disorders among Caucasians, can lead to iron overload, or a buildup of iron in the body's organs. This extra iron, which can be easily treated if detected early, can increase the risk of diabetes, arthritis, sexual dysfunction, liver disease and liver cancer and heart disease."